Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
New words:
accommodate, allied, Anthim, antidote, antiviral, Aptevo, ASU, Attached, Battelle, bear, biotechnology, bispecific, built, Burkholderia, Camden, CEO, closing, CMC, CODM, compelled, consulting, cytokine, cytotoxicity, daniel, delivery, dengue, Document, downstream, duly, EID, engineering, enrolled, enterprise, ERP, escalation, Exhibit, FASB, hand, hereto, herewith, ii, imminent, Imputation, Index, inflammatory, Instance, issuable, ITAR, Item, iv, kramer, Language, light, Linksbase, liver, Memorial, monospecific, multiple, multispecific, MVAtor, nerve, notification, notified, obiltoxaximab, older, oversight, perioperative, pipeline, preceding, prepaid, prime, prioritization, promissory, protocol, proven, quantity, Ratio, realigned, recurrence, redirected, regimen, robert, rPA, RTCC, Schema, shortage, signaling, skilled, spin, standalone, subcontract, Subtopic, surge, Taxonomy, thereunto, Traffic, turn, Ulcerative, undersigned, XBRL
Removed:
abandonment, accounted, accrual, adding, allocation, approach, autoimmunity, bacterial, capable, categorized, Category, chargeback, collectively, commonly, deferred, direction, directly, disseminated, distinct, easily, estimation, Evolva, expressing, fluctuation, goodwill, Holding, host, IIa, indirectly, infection, initiation, integrated, June, lethal, line, membrane, mix, MVAtorTM, oral, orally, overexpressed, pathogen, people, physician, priority, recognition, referred, reserve, responsible, SA, subjective, subjectivity, tolerability, topoisomerase, vivo, weaponized, wholesale, wholesaler, worldwide
Filing tables
Filing exhibits
Related press release
EBS similar filings
Filing view
External links
EXHIBIT 12
Ratio of Earnings to Fixed Charges | ||||||||||||||||||||||||
Year to Date | ||||||||||||||||||||||||
March 31, | Year Ended December 31, | |||||||||||||||||||||||
(in thousands) | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||||||||||||||||||
Pretax income from continuing operations (1) | $ | 7,339 | $ | 89,769 | $ | 53,062 | $ | 44,243 | $ | 37,446 | $ | 38,849 | ||||||||||||
Fixed charges | ||||||||||||||||||||||||
Interest expense | 1,937 | 7,834 | 7,480 | 1,973 | 2,177 | 1,719 | ||||||||||||||||||
Debt issuance cost | 382 | 1,564 | 3,290 | 319 | 67 | 135 | ||||||||||||||||||
Total fixed charges (2) | 2,319 | 9,398 | 10,770 | 2,292 | 2,244 | 1,854 | ||||||||||||||||||
Noncontrolling interest in pretax income (3) | - | - | - | 876 | 5,381 | 6,906 | ||||||||||||||||||
Capitalized interest (4) | 795 | 2,875 | 2,530 | 1,973 | 2,177 | 1,713 | ||||||||||||||||||
Earnings ((1) + (2) -(3) -(4)) | 8,863 | 96,292 | 61,302 | 43,686 | 32,132 | 32,084 | ||||||||||||||||||
Fixed charges | 2,319 | 9,398 | 10,770 | 2,292 | 2,244 | 1,854 | ||||||||||||||||||
Ratio of earnings to fixed charges | 3.8 | 10.2 | 5.7 | 19.1 | 14.3 | 17.3 | ||||||||||||||||||